熱門資訊> 正文
NRx Pharmaceuticals报告潜在的收购和融资协议
2024-08-26 20:06
- NRx Pharmaceuticals (NASDAQ:NRXP) subsidiary, HOPE Therapeutics, Monday reported the signing of a non-binding term sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions).
- In addition to the currently signed non-binding term sheet, the company has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues exceeding $100 million.
- The company anticipates potential operations in the United States, France, and the United Kingdom.
- The non-dilutive acquisition funding announced on Monday is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange.
- NRXP +4.33% premarket to $2.17.
- Source: Press Release
More on NRx Pharmaceuticals
- NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript
- NRx Pharmaceuticals announces up to $16M senior secured debt financing
- Seeking Alpha’s Quant Rating on NRx Pharmaceuticals
- Historical earnings data for NRx Pharmaceuticals
- Financial information for NRx Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
